Safeguard Scientifics Announces Second Quarter 2020 Financial Results

RADNOR, Pa., Aug. 11, 2020 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE:SFE) ("Safeguard" or the "Company") today announced financial results for the three months and six months ended June 30, 2020.

Highlights

    --  Safeguard remains committed to its stated strategy to monetize ownership
        interests in a timely manner and maximize the value for Safeguard
        shareholders.
    --  Safeguard's companies continue to respond to COVID-19 by managing cost
        structures, securing capital and adjusting operations to take advantage
        of opportunities in post COVID-19 environment.
    --  Safeguard completed follow-on funding to three companies totaling $4.4
        million in the second quarter, including $3.8 million to Syapse as part
        of an existing investor round that also expanded and restructured its
        debt facilities, bringing the year-to-date total deployed to $6.6
        million.
    --  At June 30, 2020, the carrying value of the Company's ownership
        interests totaled $61.4 million, and cash, cash equivalents and
        restricted cash totaled $13.6 million.
    --  Reduced General and Administrative expenses 30% year over year to $2.0
        million for the quarter ended June 30, 2020, including a reduction in
        Corporate expenses(1) of $1.2 million, a 36% year over year decline.
    --  Safeguard's net loss for the three months ended June 30, 2020 was $9.9
        million, or $0.48 per share, compared with net income of $36.1 million,
        or $1.75 per share, for the same period in 2019.  Safeguard's results
        for the quarter included additional non-cash impairment charges of $5.7
        million resulting from reduced expectations for certain ownership
        interests, while the prior period quarter included a gain from the sale
        of Transactis of $50 million.
    --  Safeguard's net loss for the six months ended June 30, 2020 was $25.9
        million, or $1.25 per share, compared with net income of $57.8 million,
        or $2.80 per share, for the same period in 2019.  Safeguard's results
        for the year-to-date period included non-cash impairment charges of
        $17.0 million, while the prior period included gains from the sales of
        Propeller and Transactis totaling $86 million.

"We are pleased by how the management teams of our companies have responded to the challenges posed by COVID-19," said Eric C. Salzman, Safeguard's Chief Restructuring Officer. "By and large, our companies are tracking ahead of their COVID-19 budgets, actively adapting to the current environment and in some cases finding new pockets of strength. Our team is fully engaged in the support of our companies and the actions they are taking. While the current environment may impact the time frame of expected exits for some of our companies, we are encouraged by an increase in demand in certain markets and cautiously optimistic that the activity we are seeing with strategic partners and capital providers will translate into continued recovery and increased opportunities going forward."

"We have taken action to reduce expenses while continuing to prudently evaluate deployments," said Mark A. Herndon, Safeguard's Senior Vice President and Chief Financial Officer. "Our expectation for follow-on funding requirements during the full year 2020 remains between $8 and $12 million. Corporate expenses for the year ended December 31, 2020 are expected to be at the low end, or below, our previously disclosed range of $5.6 to $6.0 million as compared to $7.1 million reported for the year ended December 31, 2019."



       
              OWNERSHIP INTERESTS AT JUNE 30, 2020




                                    Companies                      
            
              Category 
     
       Acquisition  
     
              Primary    
        
     Carrying                Cost
                                                                               Year                     Ownership%    Value
                                                                                                                                                            (in
                                                                                                                                                         millions)
                                                                                                                            (in millions)

    ---




       
              Initial Revenue Stage:  Up to $1 million in revenue



       None



       
              Expansion Stage:  $1 million to $5 million in revenue


        Moxe Health
         Corporation                                             
            Healthcare                          2016                   29.9%                   $4.9           $7.5



       
              Traction Stage:  $5 million to $10 million in revenue


        meQuilibrium                                             
            Healthcare                          2015                   32.0%  4.1                      14.0


        Trice Medical, Inc.                                      
            Healthcare                          2014                   16.6%  1.8                      10.8


        Zipnosis, Inc.                                           
            Healthcare                          2015                   37.7%  2.7                      10.0


        QuanticMind, Inc.                                        
            Digital Media                       2015                   24.2%  2.1                      13.7


        WebLinc, Inc.                                            
            Digital Media                       2014                   39.9%  1.9                      16.2


        Lumesis, Inc.                                            
            Financial Services                  2012                   43.5%  0.7                       5.6



       
              High Traction Stage:  $10 million to $15 million in revenue


        InfoBionic, Inc.                                         
            Healthcare                          2014                   25.2%                                 22.0


        Clutch Holdings,
         Inc.                                                    
            Digital Media                       2013                   41.2%  5.2                      16.8


        Sonobi, Inc.                                             
            Digital Media                       2015                   21.6%  5.5                      13.4


                   Between $15 to $20 million in revenue


        Prognos Health,
         Inc.                                                    
            Healthcare                          2011                   28.7%  4.4                      12.6



       
              Greater than $20 million in revenue


        Aktana, Inc. +                                           
            Healthcare                          2016                   17.5%  0.9                      11.7


        Syapse, Inc.                                             
            Healthcare                          2014                   19.6%  5.6                      25.0


        Flashtalking                                             
            Digital Media                       2018                   13.4% 12.5                      19.2


        MediaMath, Inc.                                          
            Digital Media                       2009                   13.3%                                 15.5



       
              Other Ownership Interests


        T-REX Group                                              
            Financial Services                  2016                          2.5                       6.0


        Velano Vascular                                          
            Healthcare                          2013                          2.0                       1.7



       All others                                               
            Various                                                          4.6                      14.4


                                                                                                    
           TOTAL:                  $61.4                    $236.1

                            + Company progressed into
                             higher revenue stage this
                             quarter.

CONFERENCE CALL AND WEBCAST DETAILS

Please call 10-15 minutes prior to the call to register.

Date: Tuesday, August 11, 2020

Time: 9 am ET

Webcast: http://www.safeguard.com/events

Live Number: 833-968-2224 // (International) 825-312-2064

Replay Number: 800-585-8367 // (International) 416-621-4642

Access Code: 2779780

Speakers: Executive Chairman of the Board, Dr. Robert J. Rosenthal; Chief Restructuring Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon

Format: Discussion of second quarter 2020 financial results followed by Q&A

Replay will be available through September 5, 2020 at 11:59 pm ET. For more information please contact IR@safeguard.com.

About Safeguard Scientifics
Historically, Safeguard Scientifics (NYSE:SFE) has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. For more information, please visit www.safeguard.com.

Forward-looking Statements
Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Safeguard's ability to maximize the value of monetization opportunities of its ownership interests and drive total shareholder returns. Safeguard's initiatives taken or contemplated to enhance and unlock value for all of its shareholders, Safeguard's efforts to execute on and implement its strategy to streamline its organizational structure, reduce its operating costs, pursue monetization opportunities for ownership interests and maximize the return of value to its shareholders, Safeguard's ability to create, unlock, enhance and maximize shareholder value, the effect of Safeguard's management succession plan on driving increased organizational effectiveness and efficiencies, the ability of the management team to execute Safeguard's strategy, the availability of, the timing of, and the proceeds that may ultimately be derived from the monetization of ownership interests, Safeguard's projections regarding the reduction in its ongoing operating expenses, Safeguard's projections regarding annualized operating expenses and expected severance expenses, monetization opportunities for ownership interests, and the amount of net proceeds from the monetization of ownership interests that will enable the return of value to Safeguard shareholders after satisfying working capital needs and the timing of such return of value. Such forward-looking statements are not guarantees of future operational or financial performance and are based on current expectations that involve a number of uncertainties, risks and assumptions that are difficult to predict. Therefore, actual outcomes and/or results may differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the monetization of our ownership interests for maximum value or at all and the return of value to our shareholders, our ability to successfully execute on our strategy to streamline our organizational structure and align our cost structure to increase shareholder value, whether our strategy will better position us to focus our resources on the highest-return opportunities and deliver enhanced shareholder value, the ongoing support of our existing ownership interests, the fact that our companies may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of our publicly traded holdings, if any, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, risks, disruption, costs and uncertainty caused by or related to the actions of activist shareholders, including that if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our shareholders and perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the direction of our business, instability or a lack of continuity that may adversely affect our business, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited operating history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond the Company's ability to predict or control. As a result of these and other factors, the Company's past operational and financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.

SAFEGUARD CONTACT:
Mark Herndon
Chief Financial Officer
(610) 975-4913
mherndon@safeguard.com

(1) Corporate expenses are general and administrative expenses excluding depreciation, severance, stock-based compensation and other non-recurring items. See full reconciliation in the financial section of this statement.


                                                  
           
               Safeguard Scientifics, Inc.

                                             
             
             Condensed Consolidated Balance Sheets

                                                        
           
                (in thousands)




                                         June 30, 2020                                                December 31, 2019



                  Assets


     Cash, cash equivalents
      and restricted cash                                   $
              13,632                                           $
       25,053


     Other current assets                                                  544                                                 1,297



     Total current assets                                               14,176                                                26,350


     Ownership interests in
      and advances                                                      61,405                                                77,129


     Other assets                                                        3,945                                                 4,098



                  Total Assets                              $
              79,526                                          $
       107,577





                  Liabilities and Equity


     Other current
      liabilities                                            $
              2,072                                            $
       2,429



     Total current
      liabilities                                                        2,072                                                 2,429


     Lease liability -
      non-current                                                        2,222                                                 2,380


     Other long-term
      liabilities                                                          918                                                 1,027


     Total equity                                                       74,314                                               101,741



                  Total Liabilities and
                   Equity                                   $
              79,526                                          $
       107,577


                                                            
          
                Safeguard Scientifics, Inc.

                                                        
        
            Condensed Consolidated Statements of Operations

                                                          
        
              (in thousands, except per share amounts)




                            
              Three Months Ended                             
              Six Months Ended


                                 
              June 30,                                      
              June 30,



                            2020                                 2019                                           2020               2019



      Operating expenses             $
              2,028                                $
              2,603                   $
         5,560     $
          5,660



      Operating loss                           (2,028)                                         (2,603)                       (5,560)          (5,660)


      Other income (loss),
       net                                     (2,658)                                           3,118                        (6,225)            1,233


      Interest, net                                 52                                          (4,919)                           157           (6,581)


      Equity income (loss),
       net                                     (5,277)                                          40,497                       (14,291)           68,764



      Net income (loss)
       before income taxes                     (9,911)                                          36,093                       (25,919)           57,756


      Income tax benefit
       (expense)



      Net income (loss)            $
              (9,911)                              $
              36,093                $
         (25,919)   $
          57,756



      Net income (loss) per
       share:



     Basic                         $
              (0.48)                                $
              1.75                  $
         (1.25)     $
          2.80




     Diluted                       $
              (0.48)                                $
              1.75                  $
         (1.25)     $
          2.80



      Weighted average
       shares used in
       computing income
       (loss) per share:



     Basic                                     20,720                                           20,628                         20,703            20,606



     Diluted                                   20,720                                           20,658                         20,703            20,606

Safeguard Scientifics, Inc.
Financial Data
(in thousands)

Additional Financial Information

Non-GAAP Measures

In discussing financial results and guidance, the Company refers to the measure "corporate expenses" which is not in accordance with Generally Accepted Accounting Principles (GAAP). We use this non-GAAP financial measure internally to make operating and strategic decisions, including evaluating our overall performance and as a factor in determining compensation for certain employees. We have defined corporate expenses as general and administrative costs excluding Depreciation, Stock based compensation, severance and retirement costs, and non-recurring items and other. Non-recurring items and other includes accruals related to the Company's LTIP plan that will not be paid until reaching a specified threshold within that plan. We believe presenting this non-GAAP financial measure provides additional information to facilitate comparison of our historical operating costs and their trends, and provides additional transparency on how we evaluate our cost structure. We also believe presenting this measure allows investors to view our performance using the same measure that we use in evaluating our performance and trends.



     
                Corporate expenses reconciliation:




                                                       Three Months Ended      
         Six Months Ended


                                                 
              June 30,               
         June 30,



                                              2020                        2019                     2020      2019



      Corporate expenses                             $
              1,242           $
         1,910           $
     2,695  $
     4,041



     Depreciation                                                                       323                         808


      Stock based compensation                                     441                    269                527       686


      Severance and retirement
       costs                                                        22                    101              1,765       125


      Non-recurring items and
       other                                                       323                                      573



      General and administrative
       expenses                                      $
              2,028           $
         2,603           $
     5,560  $
     5,660

View original content to download multimedia:http://www.prnewswire.com/news-releases/safeguard-scientifics-announces-second-quarter-2020-financial-results-301109596.html

SOURCE Safeguard Scientifics, Inc.